MIR17HG and breast cancer: In addition, MIR17HG overexpression was found to inhibit proliferation of luminal breast cancer cells by targeting a steroid receptor coactivator (NCOA3), cyclin D1 (CCND1) and estrogen receptor α (ESR1) [9–12].